期刊
CELL REPORTS
卷 10, 期 9, 页码 1614-1625出版社
CELL PRESS
DOI: 10.1016/j.celrep.2015.02.024
关键词
-
类别
资金
- Bio & Medical Technology Development Program of Korea National Research Foundation (NRF) [2010-0020258]
- Innovative Research Institute for Cell Therapy - Ministry of Health Welfare (MHW) [Innovative Research Institute for Cell Therapy (A062260]
- Korea Health Technology R&D Project through Korea Health Industry Development Institute, - MHW [HI12C16910000, HI14C1277, HI12C0199]
We investigate crosstalk between cancer cells and stromal myeloid cells. We find that Lewis lung carcinoma cells significantly induce PPAR beta/delta activity in myeloid cells in vitro and in vivo. Myeloid cell-specific knockout of PPAR beta/delta results in impaired growth of implanted tumors, and this is restored by adoptive transfer of wild-type myeloid cells. We find that IL-10 is a downstream effector of PPAR beta/delta and facilitates tumor cell invasion and angiogenesis. This observation is supported by the finding that the CD11b(low)IL-10(+) pro-tumoral myeloid cell is scarcely detected in tumors from myeloid-cell-specific PPAR beta/delta knockout mice, where vessel densities are also decreased. Fatty acid synthase (FASN) is shown to be an upstream regulator of PPAR beta/delta in myeloid cells and is induced by M-CSF secreted from tumor cells. Our study gives insight into how cancer cells influence myeloid stromal cells to get a pro-tumoral phenotype.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据